Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection

Cryptococcosis Clinical Trial

Official title:
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection

Status Completed

Clinical Trial Summary

Innate immunity plays an important role for fungal recognition and initiation of fungicidal activity. We hypothesize that subtle differences in different molecules of innate immunity may contribute to either the predisposition or clinical course of infection with Cryptococcus neoformans. To test this hypothesis, we propose to analyze the allelic frequencies of 15 different genes (mannose binding lectin, Fc-gamma receptor IIa and IIb, Fc-gamma receptors IIIa and IIIb, myeloperoxidase, tumor necrosis factor-alpha and -beta, interleukin 1A and 1B, interleukin-1 receptor antagonist, interleukin-10, NRAMP-1, chitotriosidase, and chemokine receptor 5) and their intragenic polymorphic forms and to compare this data to the incidence and severity of C neoformans infection. With this study we hope to identify a group of molecules of innate immunity which influence the risk and severity of invasive C neoformans infection.

Clinical Trial Description

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00001701
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase	N/A
Start date	July 29, 1998

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02454569` - Vicente Ferrer HIV Cohort Study
Recruiting	`NCT04033718` - Inpatient Package to Reduce HIV and AIDS-related Death in Zambia	N/A
Terminated	`NCT03002012` - Cryptococcal Antigen Screening Plus Sertraline	Phase 3
Completed	`NCT03993093` - Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Completed	`NCT05707156` - Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
Completed	`NCT01535469` - Operational Research for Cryptococcal Antigen Screening	Phase 4
Completed	`NCT00784368` - A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection	Phase 3
Recruiting	`NCT04554875` - Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
Enrolling by invitation	`NCT02503449` - Clinical Trial of Pulmonary Cryptococcosis in China	N/A
Active, not recruiting	`NCT03267407` - Vietnam Cryptococcal Retention in Care Study - Version 2.1	N/A
Completed	`NCT00647907` - A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections	Phase 4
Recruiting	`NCT00001352` - Fungal Infection Susceptibility

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.